Prelude Therapeutics (PRLD) Change in Account Payables (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Change in Account Payables data on file, last reported at -$1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 1.62% year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2026 stood at -$3.9 million (down 608.77% YoY), and the FY2025 full-year result was -$3.9 million, down 218.55% from the prior year.
• Change in Account Payables eased to -$1.9 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q3 2022 to a low of -$3.2 million in Q4 2022.
• A 5-year average of -$300529.4 and a median of -$465000.0 in 2023 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables jumped 18600.0% in 2023 and sank 1040.38% in 2025, its largest moves.
• Tracing PRLD's Change in Account Payables over 5 years: stood at -$3.2 million in 2022, then soared by 85.65% to -$465000.0 in 2023, then soared by 489.25% to $1.8 million in 2024, then slipped by 29.78% to $1.3 million in 2025, then tumbled by 247.84% to -$1.9 million in 2026.
• Business Quant data shows PRLD's Change in Account Payables at -$1.9 million in Q1 2026, $1.3 million in Q4 2025, and -$2.4 million in Q3 2025.